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Combining tumour response and progression free survival as surrogate endpoints
for overall survival in advanced colorectal cancer
Elia EG1,2∗, Sta¨dler N3, Ciani O4,5, Taylor RS4, Bujkiewicz S1
Abstract
Objectives:
To investigate whether joint modelling of two candidate surrogate endpoints, the tumour response (TR) and progres-
sion free survival (PFS), improves their predictive value of the final clinical endpoint, the overall survival (OS), in
advanced colorectal cancer.
Study Design and Setting:
Data were obtained from a systematic review of randomised control trials investigating effectiveness of a broad range
of pharmacological therapies in advanced colorectal cancer. The treatments included systemic chemotherapies, anti-
epidermal growth factor receptor (anti-EGFR) therapies, anti-angiogenic agents, other multi-targeted antifolate (MTA)
treatments and intra-hepatic arterial chemotherapy (IHA). Multivariate meta-analysis was used to model the associ-
ation patterns between treatment effects on the surrogate endpoints (PFS and TR) and the final outcome (OS). The
surrogate relationships were explored by the use of regression parameters (intercept, slope and conditional variance)
and adjusted R-squared. Analyses were conducted on data from all trials reporting relevant outcomes and in subgroups
defined by the type of therapy.
Results:
Analysis of 33 trials which reported treatment effects on all three outcomes (TR, PFS and OS) showed that there was
association between treatment effects on OS and the treatment effect on both candidate surrogate endpoints, TR and
PFS, when modelled individually and jointly. The surrogate association was particularly strong between treatment
effect on PFS and OS, with the positive slope 0.28 (95% CrI: 0.12, 0.45) and relatively small conditional variance
0.003 (95% CrI: 0.00, 0.01). The adjusted R-square was also relatively high but obtained with a large uncertainty;
0.66 (0.2, 0.97). This relationship was not improved by inclusion of the treatment effect on the second surrogate
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endpoint, the TR. There was no marked improvement in neither surrogacy patterns nor the precision of predicted
treatment effect in the cross validation procedure when modelling the treatment effect on the two outcomes jointly.
This was also the case for the subgroups of therapy, the sensitivity analysis including a larger set of data from trials
reporting treatment effects on at least two outcomes and using a smaller set of data from the trials that did not allow
for treatment crossover. There was a very modest improvement in the surrogacy pattern and the predictions obtained
from the analysis of multiple surrogate endpoints in the subgroups of the anti-angiogenic agents.
Conclusion:
Overall, the joint use of two surrogate endpoints did not lead to improvement in the association between treatment
effects on surrogate and final endpoints in advanced colorectal cancer. Only small improvement in the precision of the
predicted treatment effects on the final outcome in studies investigating anti-angiogenic therapy was noted. However,
the improvement was very modest and likely due to chance.
Keywords: surrogate endpoints, multivariate meta-analysis, advanced colorectal cancer
1. Introduction
Surrogate endpoints have been receiving increased attention by the research community in the last three decades
as they offer a cost effective and quicker alternative to the use of final outcomes especially if they can be measured
with a shorter follow-up period [1]. For surrogate endpoints to be used effectively in clinical research, they need to
be validated. There are three levels of surrogate endpoint validation: biological plausibility of association between
outcomes, patient-level association between outcomes and study-level association [2, 3]. For the purposes of this study
we focus on the latter level of validation. Study level association is the hallmark of surrogacy, i.e. establishing whether
the treatment effect on the surrogate endpoint is likely to predict a treatment effect on the clinical outcome. This is
usually carried out through meta-analyses of randomised controlled trials (RCTs) and, in particular, using a bivariate
meta-analysis [4, 5, 6].
To identify a surrogate endpoint for overall survival (OS) in advanced or metastatic colorectal cancer, a number
of candidate endpoints have been investigated as potential surrogate endpoints, including progression free survival
(PFS), tumour response (TR) or time to progression (TTP) [7, 8, 9, 10, 11, 12]. In previous work investigating trial-
level surrogacy in advanced colorectal cancer, Buyse et al found that PFS was an acceptable surrogate endpoint to
the overall survival [7]. A more recent study, investigating surrogacy patterns across a broader range of treatments
in a meta-analysis of 101 RCTs, showed suboptimal validity of PFS as a surrogate endpoint for OS in advanced or
metastatic colorectal cancer [10]. Other studies also investigated the surrogate relationship between the PFS and OS
in advanced colorectal cancer that suggested that further validation is required [8, 9].
In these previous studies, using meta-analytic techniques either in the form of a meta-regression or a bivariate meta-
analysis, only one surrogate endpoint at a time was investigated. Recently, researchers investigated use of multiple
surrogate endpoints in a patient-level surrogate endpoint validation in multiple sclerosis [13] and as joint predictors of
clinical benefit measured on final outcome in a meta-analytic framework using Bayesian multi-variate meta-analysis
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[14].
In this paper we investigate whether the use of treatment effects on two candidate surrogate endpoints, PFS and
TR, can result in increased precision of predicted treatment effect on the final outcome, namely OS, in advanced
colorectal cancer when they are modelled jointly. We investigated the predictive ability of the surrogate endpoints in
this setting by conducting a bivariate meta-analysis to investigate one surrogate endpoint at a time and a trivariate
meta-analysis to evaluate the surrogate endpoints jointly. We conducted the analysis in the Bayesian framework using
multivariate meta-anlysis method described by Bujkiewicz et al [14]. Then the added value of multiple surrogate
endpoints modelled jointly was investigated, by comparing the meta-analytic models in terms of predicted intervals.
2. Methods
2.1. Data sources
We used data from a systematic review by Ciani et al 2015 [10], which included treatment effect estimates from 101
randomised controlled trials (RCTs) in advanced or metastatic colorectal cancer that assess pharmacologic therapy
against other therapy. The studies included trials investigating a broad range of treatments including five different
classes which were systemic chemotherapy, anti-epidermal growth factor receptor monoclonal antibodies (Anti-EGFR),
anti-angiogenic agents, other multi-targeted antifolate (MTA) and intra-hepatic arterial chemotherapy (IHA). For the
purposes of the systematic review conducted by Ciani et al. [10] the following definitions of outcomes were considered:
OS was defined as the time from randomization to time of death, PFS was defined as the time from randomization to
tumour progression (regardless of how the progression was defined), or death from any cause, and TR was defined by
objective tumor measurements by utilising methods that classify patients as responders, with a complete or partial con-
firmed best response. Responses were determined using the criteria and recommendations according to the Response
Evaluation Criteria in Solid Tumors (RECiST) guidelines [15] or the World Health Organization recommendations [16].
For purpose of this paper, we used data from the above systematic review on treatment effects measured on OS,
PFS and TR. Not all of the studies in the systematic review reported treatment effects on all three outcomes of interest.
In our base case scenario analysis, we used data from trials reporting all three outcomes. As a sensitivity analysis,
we carried out an analysis on data from studies which reported treatment effects on at least two outcomes. Analyses
were repeated in subsets of data defined by the type of treatment. A sensitivity analyses to examine the impact of an
outlying observation and the choice of the prior distribution for the between-studies correlation were also carried out
(for details see section 2.2).
Crossover in RCTs, for example from the control to experimental arm following progression, often results in loss
of information about the treatment effect on the final outcome; what the effect would have been if crossover was
not allowed. As patients move to the experimental treatment arm, the difference in treatment effect on OS between
the treatment arms diminishes, leading potentially to zero effect with large uncertainty. This creates difficulty in
estimating the association patterns between treatment effects on surrogate and final endpoint and the estimates of the
latter are not reliable and their variability is reduced (potentially diminishing the correlation between the treatment
effect on the two outcomes). Another sensitivity analysis was carried out on the subset of trials which did not allow
for crossover.
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Individual patient data (IPD) were available from one of the RCT’s included in the systematic review; study by
Hurwitz et al. [17] that investigated the use of bevacizumab in combination with irinotecan, fluorouracil, and leu-
covorin in patients with metastatic colorectal cancer [17]. The IPD were used to obtain the within-study correlations
between the treatment effects on the surrogate endpoints and on the final outcome.
2.2. Statistical analysis
We used multivariate meta-analysis in a Bayesian framework to model jointly the treatment effects on one or two
surrogate endpoints and on the overall survival which was the final clinical outcome. Treatment effects on PFS and
OS were modeled using hazard ratios (HRs) and treatmet effects on TR were modelled using odds ratios (ORs). Log
scale was used to allow the assumption of normality of the effects. For studies, where there were no responders in one
of the treatment arms, continuity correction of 0.5 was added to all values of the contingency table to enable finite
odds ratio and variance estimators to be derived.
To model jointly treatment effect on two surrogate endpoints and the final outcome, we used trivariate random-
effects model, where the estimates of treatment effects on the two surrogate endpoints, log OR of TR, denoted Y1i and
log HR on PFS denoted Y2i and the treatment effect on the final outcome; log HR on OS, denoted Y3i are assumed to
be correlated and normally distributed
Y1i
Y2i
Y3i
 ∼ N


µ1i
µ2i
µ3i
 ,Σi
 , Σi =

σ21i σ1iσ2iρ
12
wi σ1iσ3iρ
13
wi
σ2iσ1iρ
12
wi σ
2
2i σ2iσ3iρ
23
wi
σ3iσ1iρ
13
wi σ3iσ2iρ
23
wi σ
2
3i
 , (1)
The trivariate distributions describe the within-study variability, with the effects Yki estimating the true treatment
effects µki in the population and σ
2
ki are the corresponding variances of the estimates of the treatment effects on
outcome k = 1, . . . , 3 in each study i and ρklwi the within-study correlations between these estimates. The elements
of the within-study variance-covariance matrix are assumed known. To describe the between-study variability we
modelled the correlated true treatment effect µki in the product normal formulation of conditional univariate normal
distributions:
µ1i ∼ N(η1, ψ21)
µ2i | µ1i ∼ N(η2i, ψ22)
η2i = λ20 + λ21 µ1i
µ3i | µ2i ∼ N(η3i, ψ23)
η3i = λ30 + λ32 µ2i
(2)
where the variances ψ2k, k = 1, 2, 3 relate to the between-study heterogeneity parameters τ
2
k ; ψ
2
1 = τ
2
1 , ψ
2
2 = τ
2
2 −λ221τ21
and ψ23 = τ
2
3 − λ232τ22 , with the regression coefficients related to both the heterogeneity parameters and the between-
studies correlations ρklb : λ21 = ρ
12
b
τ2
τ1
, λ32 = ρ
23
b
τ3
τ2
. In the Bayesian framework the parameters are given prior
distributions. The between-studies correlations are given informative prior distributions as recommended by Burke et
al [18]. By assuming that an increase in the treatment effect on PFS (reduced progression rate) will lead to an increased
effect on OS (reduced mortality rate) and hence a positive correlation, we place a uniform prior distribution allowing
only positive values between zero and one for the correlation is used; ρ23b ∼ U(0, 1). In a similar manner, assuming
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that increased response rate would lead to reduced progression or mortality rates, and hence a negative correlation,
we place prior distribution that allows only negative values between minus one and zero on the correlations between
treatment effects on TR and PFS and between the effects on TR and OS; ρ12b , ρ
13
b ∼ U(−1, 0). Sensitivity analysis
was carried out using a non-informative prior distribution U(-1,1) for between-studies correlation. The heterogeneity
parameters are given half normal distributions, τ1,2,3 ∼ N(0, 1000)I(0, ), to allow only for positive values [6]. The
remaining parameters are given non-informative normal prior distributions; η1 ∼ N(0, 1000), λ20, λ30 ∼ N(0, 1000).
In the above model describing the between-studies variability, we used structured between-studies variance-covariance
matrix by assuming conditional independence between the true treatment effects on the first surrogate endpoint µ1i
and on the final outcome µ3i. As a sensitivity analysis we also used an alternative model using unstructured variance-
covariance matrix and another model with a different structure on the variance-covariance matrix where the true
treatment effects on the two surrogate endpoints, µ1i and µ2i, were assumed conditionally independent.
As stated above, the within-study correlations are assumed to be known. However, to obtain the correlations, IPD
are necessary as the correlations between treatment effects on log HR and log OR scales are not reported in the original
RCT reports. For the purposes of this study, IPD from only one study were available [17]. Within-study correlations
between the treatment effects on the three outcomes (TR, PFS and OS) were obtained using bootstrapping methods
with 5000 bootstrap samples [19]. We assume that the within-study correlations were equal across all studies.
Two models were considered, the bivariate and the trivariate random effects models. The bivariate model was used
to describe and evaluate the association between treatment effects on a single surrogate endpoint (PFS or TR) and
on the final outcome (OS), whilst the trivariate model was used to describe the association between treatment effects
on multiple surrogates (PFS and TR) jointly and treatment effect on the final outcome (OS). The trivariate model
described by the formulae (1)-(2) reduces to bivariate meta-analytic model when there are only two outcomes. More
details on product normal formulation of the bivariate model for surrogate endpoints can be found in Bujkiewicz et
al. [6] and for the trivariate (and multivariate) model for multiple surrogate endpoints in Bujkiewicz et al. [14] and
for borrowing of strength across outcomes with missing data in Bujkiewicz et al [20].
2.2.1. Surrogacy relationship evaluation
We followed the surrogacy criteria introduced by Daniels and Hughes [4], and adopted by Bujkiewicz et al. [14], by
which the slope in (2), λ32, indicates the association between the treatment effect on the second surrogate endpoint
(PFS) and the treatment effect on the final outcome (OS). For the treatment effects to be associated, we require the
slope λ32 6= 0. For the association to be perfect the conditional variance ψ23 = 0. Moreover, we would expect the
intercept λ30 = 0 to ensure that no treatment effect on surrogate endpoint will imply no treatment effect on the final
outcome. In a similar manner we can describe surrogacy criteria between the first and second surrogate; λ21 6= 0,
ψ22 = 0 and λ20 = 0, where the second surrogate becomes the final outcome in a bivariate model with a single surrogate
endpoint.
We also report the adjusted R2 [21, 22] which for perfect surrogacy relationship should be one. In our model
R2adj,23 = λ
2
32
τ22
τ23
for the relationship between treatment effects on the second surrogate endpoint and on the final
outcome.
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2.2.2. Cross validation and model comparison
In order to investigate whether the joint use of treatment effects on multiple surrogate endpoints gives more precise
predictions of the treatment effect on the final outcome, a cross-validation procedure was carried out. In one study
at a time the treatment effect on the final outcome was assumed unknown and predicted from the treatment effect on
surrogate endpoint (or multiple surrogate endpoints jointly) using the bivariate (or trivariate) meta-analytic model.
In this Bayesian approach to multivariate meta-analysis, this was achieved by assuming that the unreported outcomes
were missing at random, which were then predicted by the Markov chain Monte Carlo (MCMC) simulation of the
model [20]. The predicted interval was obtained by assuming the variance σ3i (or σ2i in the bivariate case) of the
treatment effect on the final outcome known and inflating it by the variance of the random effect giving the variance
of the predicted effect σ23n + var(µˆ3n|Y1n, Y2n, σ1n, σ2n, Y1(−n), Y2(−n), Y3(−n)), where Y1(2,3)(−n) denote the data from
the remaining studies without the validation study n, similarly as in Daniels and Hughes [4]. The added value of
multiple surrogate endpoints modelled jointly was then investigated by comparing the parameters describing criteria
for surrogacy (slope, intercept and conditional variance) and the predicted effects obtained from the cross-validation
procedure. The predicted effects on the final outcome obtained by the bivariate and the trivariate meta-analytic
models were compared in terms of the width of the predicted intervals. We investigated surrogacy across all RCTs as
well as in subgroups of class of therapy.
2.3. Software and computing
All models were implemented in WinBUGS [23] where the estimates were obtained using MCMC simulation using
250000 iterations (including 150000 burn-in). Convergence was checked by visually assessing the history, chains
and autocorrelation using graphical tools in WinBUGS. All posterior estimates are presented as means with the
95% credible intervals (CrI). R was used for data manipulation and to execute WinBUGS code multiple times (for
validation of surrogates for each study) using the R2WinBUGS package [24]. OpenBUGS and R2OpenBUGS version
of the software was used for the cross-validation procedures which were conducted using Linux (Red Hat, Inc., Raleigh,
North Carolina)-based high performance computer. WinBUGS programs corresponding to the bivariate and trivariate
models are included in the online appendix.
3. Results
3.1. Included data
Out of the 101 RCT’s 99 reported estimates of treatment effects on at least one of the three outcomes, 51 studies
reported the treatment effects on at least two of the outcomes and 33 studies reported treatment effects on all three
outcomes. In the base case analysis of data from studies reporting all three outcomes (33 studies), subgroups of
therapy included 15 studies which investigated the use of systemic chemotherapy, eight studies which evaluated the
use of anti-EGFR therapies, nine studies investigating the use of anti-angiogenic agents and one study evaluating the
use of IHA. More details about the study characteristics are included in Ciani et al [10].
In the sensitivity analysis of studies reporting at least two outcomes, we used 51 of which: 48 studies invastigated
OS (23 Systemic Chemotherapy, 11 anti-EGFR, 12 anti-angiogenic agents, 1 MTA, 1 IHA), 39 studies investigated
PFS (17 Systemic Chemotherapy, 9 anti-EGFR, 12 anti-angiogenic agents, and 1 IHA), and 48 studies investigated TR
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(25 Systemic Chemotherapy, 10 anti-EGFR, 11 anti-angiogenic agents, 1 MTA, 1 IHA). The results obtained from the
trivariate meta-analysis, where at least two outcomes were reported (with some missing data), were compared to the
bivariate analysis of the complete data for each surrogacy pair: 45 studies investigated both TR and OS (23 Systemic
Chemotherapy, 10 anti-EGFR, 10 anti-angiogenic agents, 1 MTA and 1 IHA); 36 studies investigated TR abd PFS
(17 Systemic Chemotherapy, 8 anti-EGFR, 10 Anti-angiogenic agents, 1 IHA); 36 studies investigated PFS and OS
(15 Systemic Chemotherapy, 9 anti-EGFR, 11 Anti-angiogenic agents and 1 IHA).
In the sensitivity analysis of trials that did not allow for patient crossover we combined seven studies, out of the
total 33 trials reporting all three outcomes. The studies included three trials of systemic chemotherapy, one anti-EGFR
therapy, two anti-angiogenic agents and one IHA.
List of references for studies included in the analysis can be fount in the supplementary materials.
Exploratory analysis of the data (presented graphically in Figures 1 to 4 and Table 1 of the supplementary materials)
showed a lot of heterogeneity of the treatment effects for TR and PFS, with the confidence intervals of the treatment
effects on TR particularly wide, especially for two classes of therapy: the chemotherapy and anti-EGFR therapies.
3.2. Within-study correlations
The within-study correlations required to populate the within-study variance covariance matrix in the multivariate
meta-analytic model, were obtained from IPD. The within-study correlations between each pair of treatment effects
on the three endpoints are as follows: the correlation between treatment effects on PFS and OS (log HR(PFS) and log
HR(OS)) is ρ32wi= 0.513, correlation between treatment effects of TR and OS (log OR(TR) and log HR(OS)) is ρ
31
wi=
-0.333 and the correlation between treatment effects on TR and PFS ((log OR(TR) and log HR(PFS)) is ρ21wi= -0.433.
3.3. Surrogacy criteria: base case scenario
Three bivariate meta-analyses were carried out investigating the association between treatment effect on each pair
of the three outcomes: TR, PFS and OS. Treatment effect on TR was evaluated as a surrogate to the treatment effect
on PFS and to treatment effect on OS and the treatment effect on PFS was investigated as surrogate to treatment
effect on OS. Trivariate model was then used to investigate whether treatment effects on both TR and PFS modelled
jointly improved their predictive value of the treatment effect on OS. Table 1 shows results of these analyses conducted
in the base case scenario where the data used were from studies reporting treatment effects on all of the three outcomes.
Results of the three bivariate models applied to all of the data, presented in the top part of Table 1, showed
that there was an association between the treatment effects on each pair of outcomes. The intervals of the intercepts
obtained from the bivariate models all contained zero indicating that no effect on the surrogate endpoint could imply
no effect on the final outcome. The intervals for the slopes did not contain zero indicating positive association were
slope was positive and negative association where slope was negative. However the surrogate relationships were not
strong. When investigating TR as a surrogate endpoint for OS, the association between the treatment effects on the
two outcomes was weak in terms of the small slope λ21= -0.05 (95%CrI: -0.13,0.00) and the 95% CrI contained zero
when rounded to the second decimal place, and the mean and the lower bound of R2adj = 0.33 (95% CrI: 0.00, 0.91)
were also small. The slope and the adjusted R-squared were higher for the relationship between the treatment effects
on PFS and TR; slope was -0.32 (95% CrI: -0.45, -0.20) and R2adj = 0.61 (95% CrI: 0.27, 0.87). However the lower
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TR OS TR PFS TR PFS PFS OS PFS OS
2D 2D 3D 2D 3D
All treatments (N=33)
intercept -0.03(-0.07,0.02) -0.05(-0.14,0.02) -0.05(-0.13,0.02) -0.02(-0.06,0.03) -0.02(-0.06,0.03)
slope -0.05(-0.13,0) -0.32(-0.45,-0.2) -0.31(-0.43,-0.19) 0.22(0.03,0.41) 0.19(0.02,0.4)
variance 0(0,0.01) 0.02(0.01,0.05) 0.02(0.01,0.04) 0(0,0.01) 0(0,0.01)
R2adjusted 0.33(0,0.91) 0.61(0.27,0.87) 0.64(0.3,0.89) 0.58(0.06,0.97) 0.5(0.02,0.95)
Systemic chemotherapy (N=15)
intercept -0.02(-0.08,0.04) -0.04(-0.16,0.06) -0.04(-0.14,0.05) -0.02(-0.08,0.04) -0.02(-0.08,0.04)
slope -0.03(-0.11,0) -0.26(-0.42,-0.08) -0.25(-0.4,-0.09) 0.17(0,0.45) 0.14(0,0.4)
variance 0(0,0.01) 0.02(0,0.08) 0.02(0,0.06) 0(0,0.01) 0(0,0.01)
R2adjusted 0.39(0,0.96) 0.58(0.07,0.96) 0.66(0.11,0.98) 0.52(0.01,0.98) 0.47(0,0.97)
Anti-EGFR therapies (N=8)
intercept -0.06(-0.16,0.09) -0.21(-0.37,0.01) -0.18(-0.37,0.05) -0.06(-0.16,0.14) -0.04(-0.16,0.19)
slope -0.04(-0.18,0) -0.14(-0.36,-0.01) -0.16(-0.39,-0.02) 0.14(0,0.63) 0.17(0,0.78)
variance 0.01(0,0.05) 0.02(0,0.08) 0.02(0,0.1) 0.01(0,0.04) 0.01(0,0.05)
R2adjusted 0.19(0,0.82) 0.45(0,0.96) 0.5(0.01,0.97) 0.22(0,0.85) 0.19(0,0.83)
anti-angiogenic agents (N=9)
intercept 0.04(-0.09,0.2) 0.03(-0.18,0.25) 0.03(-0.18,0.25) 0.02(-0.1,0.15) 0.02(-0.09,0.14)
slope -0.35(-0.89,-0.03) -0.87(-1.64,-0.3) -0.85(-1.64,-0.27) 0.38(0.05,0.79) 0.37(0.04,0.77)
variance 0.02(0,0.07) 0.04(0,0.15) 0.03(0,0.14) 0.02(0,0.06) 0.01(0,0.06)
R2adjusted 0.52(0.01,0.97) 0.74(0.13,0.99) 0.72(0.1,0.99) 0.59(0.03,0.97) 0.56(0.02,0.97)
Table 1: Surrogacy criteria obtained from bivariate (2D) and trivariate (3D) models for the association between treatment effect on surrogate
(TR or PFS) and final outcome (OS and PFS in bivariate case). The results are posterior means and 95% credible intervals. TR – tumor
response, PFS – progression free survival, OS – overall survival
bound of the CrI for the R-squared was still low and the conditional variance was relatively high, 0.02 (95% CrI: 0.01,
0.05), indicating a weak surrogate relationship. The surrogate relationship between the treatment effects on PFS and
OS appeared stronger in terms of the conditional variance 0.00 (95% CrI: 0.00, 0.01) and the R2adj = 0.58 (95% CrI:
0.06,0.97) with lower ends of CrIs being close to zero.
Results from the trivariate meta-analysis, which described the associations between the treatment effects on the
two pairs of outcomes (effects on PFS and TR and effects on OS and PFS) in a single model, were similar to those
obtained from separate bivariate models. Precision around the intercept, slope and the conditional variance was
minimally reduced for the association between the treatment effects on PFS and TR in the trivariate analysis whereas
precision for these estimates for the association between the treatment effects on OS and PFS remained the same in
the trivariate analysis as in the the bivariate analysis using a single surrogate endpoint.
Table 1 also shows the results for each subclass of therapy. For subgroup of trials investigating systemic chemother-
apy, the results were similar to those obtained from the whole cohort of studies but typically obtained with increased
uncertainty (wider CrIs) and weaker association in terms of lower mean slope. The adjusted R-squared was minimally
higher in this subgroup for the association between the treatment effects on OS and TR, whilst a lower mean slope
was obtained for the association between TR and PFS and between PFS and OS, compared to the analysis of all
treatments. The slopes for the association between the treatment effects on TR and PFS and between the effects on
OS and PFS were obtained with minimally higher precision from the trivariate models compared to the bivariate. For
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the anti-EGFR therapies, also similar results were obtained to those from the analysis conducted on data from all of the
studies but also, similarly as for systemic chemotherapy, with weaker association pattern. For anti-angiogenic agents
the mean slopes and the mean R-squared values were considerably higher for all investigated surrogacy relationships
compared to other subclasses and the analysis of all treatments, however they were obtained with high uncertainty,
also likely due to the small number of studies in the subgroup.
3.4. Cross-validation
To investigate the predictive value of the surrogate endpoints when modelled jointly, a cross-validation procedures
were carried out. The predicted treatment effects on OS predicted from the treatment effect on PFS alone were com-
pared with those predicted from treatment effects on both TR and PFS jointly by exploring the associated uncertainty
described by the predicted intervals as well as whether the predicted intervals contained the observed point estimate
of the treatment effect on OS in each study. When looking at predicted treatment effects obtained using the complete
data set of the 33 studies, some of the predicted intervals were inflated when making predictions from the treatment
effect on both surrogate endpoints jointly, compared to the predictions made from the treatment effect on PFS only.
The intervals were on average 0.21% wider with the percentage change of the width of the interval ranging between
1.96% reduction to 4.4% increase. However, from the point of view of the cross-validation procedure, the 95% predicted
intervals included the observed point estimate in most of the studies apart from one which was an extreme lowest
value of the treatment effect on OS. This was the case for both bivariate and trivariate models. Full set of predicted
intervals is included in Table 2 of the supplementary materials.
The cross-validation procedure was repeated for each class of therapy separately. In terms of predicted intervals,
on average there was a very modest improvement in precision of predictions for the anti-angiogenic agents obtained
from the trivariate compared to the bivariate model (on average 2.35% narrower 95% predicted interval). For the
systemic chemotherapy class there was a minimal improvement in precision for most of the studies, with an average
percentage reduction of 1.41% predicted interval. However, the predicted intervals were inflated for the anti-EGFR
therapies with, on average, 6.9% increase in the width of the interval. All predicted intervals are included in Table 3
of the supplementary materials.
Overall there was not much benefit of combining treatment effects on two surrogate endpoints to predict the
treatment effect on the final outcome. This lack of improvement, or even increased uncertainty of the predicted
effect when using multiple surrogate endpoints, may be due to increased overall between-studies heterogeneity when
extending the data to include the treatment effect on TR. The between-studies heterogeneity for the treatment effect
on TR was considerably higher compared to the heterogeneity of the treatment effects on PFS and OS in the data
set including all treatments. This was also the case for the subgroups of studies including the systemic chemotherapy
and the anti-EGFR therapy trials. However, for the anti-angiogenic agents, the between-studies heterogeneity of the
treatment effect on TR was comparable with that for the treatment effects on PFS. This may explain some increase in
precision of the slope and the predicted effects on OS when using multiple surrogate endpoints in this class of therapy,
as including additional outcome did not increase overall uncertainty. However, due to small number of studies the
added value was minimal. The treatment effects on all three outcomes are comparable between those from bivariate
and trivariate models. All mean treatment effects and the heterogeneity parameters are listed in Table 1 of the
supplementary materials.
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3.5. Sensitivity analysis
Sensitivity analysis, extending the data set to the 51 studies reporting at least two outcomes gave similar results;
surrogacy criteria for the association between the treatment effects on PFS and OS were satisfied both when looking
at all therapies, and for Systemic chemotherapy and Anti-angiogenic agents therapies (Tables 4 and 5 in the online
Appendix).
Results of the sensitivity analysis of trials with no crossover, presented in Table 2, were similar to those obtained
from base case scenario with respect to the surrogacy criteria. The treatment effects on the surrogate and final outcomes
appeared to be associated for all investigated surrogacy relationships. However for all sets of surrogacy relationships
and both the bivariate and the trivariate analyses all estimates were obtained with large uncertainty compared to the
whole set of studies, which was most likely due to the small number of studies (only 7) in the meta-analysis. The
association between treatment effects on OS and PFS appeared to be weaker in terms of the conditional variance
which increased compared to the results obtained from all 33 studies reporting all three outcomes. This was the case
in both sets of results, from the bivariate and the trivariate analyses. This also led to reduced values of the adjusted
R-squared. The use of multiple surrogate endpoints did not improve the strength of the association patterns when
compared to the use of a single surrogate endpoint in this subset of studies. Similarly as for the full data set, this could
also be due to the large heterogeneity of the treatment effects on TR (see table 6 in the online appendix, including the
average effects and the heterogeneity parameters.
The cross validation showed on average a very modest increase in precision, by on average 2.3% and up to 6.2%,
when predicting the treatment effect on OS from the treatment effects on both PFS and TR compared to the predictions
made from the effect on PFS only. Full set of results from the cross validation are included in Table 7 of the online
appendix.
An additional sensitivity analysis was carried out to investigate an impact of an outlying observation (study with
the largest effect size estimate for TR). The results (listed in Table 8 of the online appendix) showed an increased
mean slope and the mean R-squared for the full set of studies and the subgroups of the EGFR inhibitors, however the
uncertainty around these parameters in both sets of results also increased.
A final sensitivity analysis was carried out investigating the impact of the choice of the prior distribution for
the between-studies correlation, replacing the informative prior distributions U(-1,0) for the negative association and
U(0,1) for the positive association with a non-informative prior distribution U(-1,1). The results of this analysis were
somewhat different compared to those obtained from the main analysis and are listed in Table 9 of the online appendix.
The association between PFS and OS, and also for TR and PFS was satisfied for both 2D and 3D models applied to
all treatments in the base case scenario. In terms of subclass therapies the association was preserved between TR and
PFS for: Systemic chemotherapy and Anti-angiogenic agents.
4. Discussion
We investigated the use of multiple surrogate endpoints as joint predictors of the clinical benefit measured on the
final clinical outcome in advanced colorectal cancer. A multivariate meta-analytic framework allowed us to combine
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TR OS TR PFS TR PFS PFS OS PFS OS
2D 2D 3D 2D 3D
intercept -0.04(-0.15,0.09) -0.05(-0.2,0.11) -0.05(-0.2,0.1) -0.03(-0.14,0.11) -0.03(-0.15,0.1)
slope -0.1(-0.32,0) -0.31(-0.64,-0.05) -0.31(-0.64,-0.05) 0.28(0.01,0.88) 0.27(0,0.88)
variance 0.01(0,0.04) 0.02(0,0.08) 0.02(0,0.08) 0.01(0,0.04) 0.01(0,0.04)
R2adjusted 0.4(0,0.96) 0.63(0.03,0.99) 0.64(0.03,0.99) 0.42(0,0.97) 0.4(0,0.96)
Table 2: Surrogacy criteria obtained from the bivariate models and trivariate model applied to the trials that did not allow for the
treatment crossover. TR – tumor response, PFS – progression free survival, OS – overall survival, 2D – bivariate model using a single
surrogate endpoint, 3D – trivariate model with treatment effects on two surrogate endpoints
treatment effects on two candidate surrogate endpoints (TR and PFS) and the treatment effect on the final clinical
outcome (OS). In a Bayesian meta-analytic framework, we modelled the correlated treatment effect in the product
normal formulation which is a convenient form to explore a range of parameters describing the surrogacy relationships,
such as the intercept, slope, conditional variance (as set out by Daniels and Hughes [4]) and the adjusted R-squared
(introduced by Burzykowski et al [22] and in the Bayesian framework by Renfro et al [21]). These models also are
used to make predictions of the treatment effect on the final clinical outcome (OS) from the treatment effect on the
surrogate endpoints. In this respect they have an advantage of taking into account of the uncertainty around all the
parameters, including the measurement error around the treatment effects on surrogate endpoints (in contrast to, for
example, the standard approach to meta-regression where treatment effects on surrogate endpoints are treated as fixed
covariates) [14].
The treatment effects on PFS and TR were associated with treatment effect on OS. However, overall the joint
use of two surrogate endpoints did not lead to much improvement in the association between treatment effects on the
surrogate and final endpoints but in the subclass of anti-angiogenic agents led to very modest improvement in preci-
sion of the predicted effects on OS. Some small improvement in precision, when modelling both surrogate endpoints
jointly, was also observed in cross-validation procedure conducted on trials without cross-over. In the trials allowing
for cross-over, there is typically reduced effect on OS with large uncertainty around the treatment effect estimate. This
is likely to affect the results of modelling surrogate relationships, using both the bivariate and the trivariate methods.
It is possible that the trivariate approach would show some noticeable benefit if more studies were available in the
analysis of studies without the cross-over. In our analysis of the trials which did not allow for the cross-over, there
was typically reduced uncertainty of the predicted effects when using multiple surrogates, but the reduction was small
as the number of studies in the analysis was also small, therefore we cannot draw strong conclusions based on our
findings. Not all studies reported whether the treatment cross-over was allowed. Another source of uncertainty that
may have prevented the improvement of the surrogate relationship when using both candidate surrogate endpoints was
the large between-studies heterogeneity of the treatment effect on the tumour response. This may have been caused
by the heterogeneity of the methods used to measure the response across the trials.
To investigate sensitivity of the results to the model parameterisation, we carried out a sensitivity analysis, (the
results of which are shown in Table 6 of the online appendix). Using alternative assumptions about the between-studies
variance-covariance structure gave similar results for the surroagte relationship between the treatment effects on PFS
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and OS, however the R2adjusted was reduced compared to the bivariate and trivariate models considered in the main anal-
ysis, and for one of the models the interval of the slope included zero suggesting marginally poor surrogate relationship.
In conclusion, the impact of the joint modelling of the treatment effects on two surrogate endpoints (TR and
PFS), on their surrogate relationship with the treatment effect on the overall survival was not noticeable in advance
colorectal cancer. Further work will be needed to investigate in detail the treatment cross-over and the heterogeneity
of the definitions of the outcomes and potentially the patient populations.
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Appendix A. WinBUGS codes for bivariate and trivariate models
Appendix A.1. Bivariate model for PFS and OS
model{
for (i in 1:num) {
rho_w[i] <-0.513
prec_w[i,1:2,1:2] <- inverse(delta[i,1:2,1:2])
#covariance matrix for the j-th study
delta[i,1,1]<-var[i,1]
delta[i,2,2]<-var[i,2]
delta[i,1,2]<-sqrt(delta[i,1,1])*sqrt(delta[i,2,2])*rho_w[i]
delta[i,2,1]<-sqrt(delta[i,1,1])*sqrt(delta[i,2,2])*rho_w[i]
}
#Random effects model
for (i in 1:num) {
Y[i,1:2]~dmnorm(mu[i,1:2], prec_w[i,1:2,1:2])
# product normal formulation for the between study part:
mu[i,1]~dnorm(rel,prec_rel)
mu[i,2]~dnorm(edss[i],prec_dis)
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edss[i]<-lambda0+lambda1*mu[i,1]
}
rel~dnorm(0.0, 0.001)
prec_rel<-1/psi1.sq
prec_dis<-1/psi2.sq
lambda0~dnorm(0.0, 1.0E-3)
# prior between study correlations:
bcorrOSpfs~dunif(0,1)
bcorr2<-pow(bcorrOSpfs,2)
sd.log.HR.pfs~dnorm(0,0.001)I(0,)
sd.log.HR.os~dnorm(0,0.001)I(0,)
psi1.sq<-sd.log.HR.pfs*sd.log.HR.pfs
sd.2.pfs<-psi1.sq
sd.2.os<-sd.log.HR.os*sd.log.HR.os
#implied prior for lambda coefficients
lambda1<-bcorrOSpfs*sd.log.HR.os/sd.log.HR.pfs
psi2.sq<-pow(sd.log.HR.os,2) - pow(lambda1,2)*pow(sd.log.HR.pfs,2)
# estimates:
mean.log.HRpfs<-rel
mean.log.HR.os<-lambda0+lambda1*rel
mean.HR.pfs<-exp(mean.log.HRpfs)
mean.HR.os<-exp(mean.log.HR.os)
rhr.meanpfs.by.meanhros<-mean.HR.pfs/mean.HR.os
}
Appendix A.2. Trivariate model model for PFS, TR and OS
Model {
for (i in 1:num) {
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rho_w_DM[i]<- -0.333 # response os
rho_w_RM[i]<- -0.433 # response pfs
rho_w_RD[i]<- 0.513 # pfs os
Prec_w[i,1:3,1:3] <- inverse(delta[i,1:3,1:3])
#covariance matrix for the j-th study
delta[i,1,1]<-var[i,1]
delta[i,2,2]<-var[i,2]
delta[i,3,3]<-var[i,3]
delta[i,1,2]<-sqrt(delta[i,1,1])*sqrt(delta[i,2,2])*rho_w_RM[i]
delta[i,2,1]<-delta[i,1,2]
delta[i,1,3]<-sqrt(delta[i,1,1])*sqrt(delta[i,3,3])*rho_w_DM[i]
delta[i,3,1]<-delta[i,1,3]
delta[i,2,3]<-sqrt(delta[i,2,2])*sqrt(delta[i,3,3])*rho_w_RD[i]
delta[i,3,2]<-delta[i,2,3]
}
# Random effects model
for (i in 1:num) {
Y[i,1:3]~dmnorm(mu[i,1:3], Prec_w[i,1:3,1:3])
# product normal formulation for the between study part:
mu[i,1]~dnorm(etaM,precM)
mu[i,2]~dnorm(etaR[i],precR)
etaR[i]<-lambda20+lambda21*(mu[i,1])
mu[i,3]~dnorm(etaD[i],precD)
etaD[i]<-lambda30+lambda23*(mu[i,2])
}
etaM~dnorm(0.0, 0.001)
lambda30~dnorm(0.0, 1.0E-3)
lambda20~dnorm(0.0, 1.0E-3)
bcorr12~dunif(-1,0)
bcorr32~dunif(0,1)
bcorr31<-bcorr12*bcorr32
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bcorr31.sq<-pow(bcorr31,2)
bcorr12.sq<-pow(bcorr12,2)
bcorr32.sq<-pow(bcorr32,2)
sd.res~dnorm(0,0.001)I(0,)
sd.dis~dnorm(0,0.001)I(0,)
sd.pfs~dnorm(0,0.001)I(0,)
tau1.sq<-pow(sd.res,2)
tau3.sq<-pow(sd.os,2)
tau2.sq<-pow(sd.pfs,2)
psi1.sq<-pow(sd.res,2)
precM<-1/psi1.sq
psi2.sq<-pow(sd.pfs,2) - pow(lambda21,2)*pow(sd.res,2)
precR<-1/psi2.sq
psi3.sq<-pow(sd.os,2) - pow(lambda23,2)*pow(sd.pfs,2)
precD<-1/psi3.sq
mean.res<-etaM #mean log OR response
mean.pfs<-lambda20+lambda21*etaM #mean log hr pfs
mean.os<-lambda30+lambda23*mean.pfs
lambda21<-bcorr12*sd.pfs/sd.res
lambda23<-(bcorr32*sd.os/sd.pfs )
meanORresp<-exp(mean.res)
meanHRpfs<-exp(mean.pfs)
meanHRos<-exp(mean.os)
rhr.meanpfs.by.meanhros<-meanHRpfs/meanHRos
}
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Appendix B. Summary of the data
Figure 1 shows forest plots for the treatment effect on the three outcomes: TR, PFS and OS. on log OR, log
HR and logHR scales respectively. Figures 2-4 include the scatter plots showing the association patterns between the
treatment effects on each pair of the three outcomes.
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Figure B.2: Scatter plot of effect size estimate for each subclass therapy for the base case scenario for outcomes: PFS (log hazard ratio),
OS (log hazard ratio)
Figure B.3: Scatter plot of effect size estimate for each subclass therapy for the base case scenario for outcomes: Tumour Response (log
odds ratio ), OS (log hazard ratio)
Figure B.4: Scatter plot of effect size estimate for each subclass therapy for the base case scenario for outcomes: Tumour response (log
odds ratio), PFS (log hazard ratio)
Appendix C. Additional results from base case scenario
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1D TR 1D PFS 1D OS 2D TR PFS 2D TR OS 2D PFS OS 3D
All treatments
mean(OR(TR)) 1.49(1.18,1.85) 1.52(1.21,1.88) 1.46(1.17,1.81) 1.52(1.21,1.88)
mean(HR(PFS)) 0.82(0.74,0.9) 0.83(0.76,0.91) 0.82(0.75,0.9) 0.83(0.76,0.91)
mean(HR(OS)) 0.95(0.91,0.99) 0.95(0.91,0.99) 0.94(0.9,0.99) 0.95(0.91,0.99)
τ2TR 0.36(0.19,0.65) 0.36(0.19,0.63) 0.36(0.19,0.64) 0.36(0.19,0.65)
τ2PFS 0.07(0.04,0.13) 0.06(0.03,0.11) 0.06(0.03,0.11) 0.05(0.03,0.1)
τ2OS 0(0,0.01) 0(0,0.02) 0.01(0,0.02) 0.01(0,0.02)
Systemic chemotherapy
mean(OR(TR)) 1.31(0.87,1.89) 1.32(0.88,1.9) 1.29(0.84,1.88) 1.3(0.87,1.86)
mean(HR(PFS)) 0.89(0.76,1.02) 0.9(0.78,1.02) 0.89(0.77,1.02) 0.9(0.79,1.02)
mean(HR(OS)) 0.97(0.91,1.02) 0.97(0.91,1.03) 0.96(0.9,1.03) 0.97(0.91,1.03)
τ2TR 0.53(0.21,1.23) 0.5(0.2,1.16) 0.56(0.22,1.3) 0.51(0.2,1.16)
τ2PFS 0.07(0.02,0.17) 0.06(0.02,0.15) 0.06(0.02,0.14) 0.05(0.02,0.12)
τ2OS 0(0,0.01) 0(0,0.01) 0(0,0.02) 0(0,0.01)
anti-EGFR therapies
mean(OR(TR)) 2.57(1.34,4.88) 2.66(1.36,5.12) 2.64(1.28,5.45) 2.81(1.33,5.75)
mean(HR(PFS)) 0.71(0.6,0.83) 0.72(0.62,0.83) 0.71(0.58,0.85) 0.72(0.6,0.85)
mean(HR(OS)) 0.9(0.82,0.99) 0.91(0.82,1.01) 0.9(0.82,0.99) 0.91(0.82,1.01)
τ2TR 0.71(0.11,2.91) 0.73(0.12,2.94) 0.91(0.13,3.87) 0.96(0.14,3.92)
τ2PFS 0.04(0,0.17) 0.03(0,0.13) 0.06(0.01,0.23) 0.05(0.01,0.18)
τ2OS 0.01(0,0.04) 0.01(0,0.06) 0.01(0,0.06) 0.01(0,0.06)
Anti-angiogenic agents
mean(OR(TR)) 1.31(0.96,1.8) 1.34(0.98,1.86) 1.3(0.96,1.78) 1.33(1,1.82)
mean(HR(PFS)) 0.82(0.6,1.08) 0.82(0.61,1.07) 0.82(0.61,1.06) 0.83(0.63,1.06)
mean(HR(OS)) 0.96(0.81,1.12) 0.96(0.82,1.1) 0.95(0.8,1.1) 0.95(0.81,1.1)
τ2TR 0.17(0.02,0.62) 0.19(0.03,0.63) 0.16(0.02,0.57) 0.16(0.02,0.52)
τ2PFS 0.19(0.04,0.6) 0.16(0.04,0.49) 0.16(0.04,0.49) 0.14(0.03,0.4)
τ2OS 0.04(0,0.16) 0.04(0,0.15) 0.04(0,0.17) 0.04(0,0.13)
Table C.3: Heterogeneity and summary measures and associated 95% Credible Intervals obtained from the bivariate and structured trivariate
models, applied to the complete data; surrogate outcomes TR: Treatment response rate, PFS: Progression free survival and final outcome
OS: Overall survival, 1D:Univariate model Posterior mean (95% CrI), 2D: Bivariate model Posterior mean (95% CrI), 3D: Trivariate model
Posterior mean (95% CrI)
Appendix D. Additional results from sensitivity analyses
Appendix D.1. Set of 51 trials reporting at least two outcomes
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Study index Observed OS bivariate trivariate structured %red
1 0.99(0.88,1.12) 1(0.84,1.18) 0.99(0.83,1.18) 0.04
2 1.01(0.74,1.38) 1(0.71,1.4) 0.99(0.71,1.38) 1.02
3 0.91(0.68,1.21) 0.87(0.63,1.2) 0.89(0.65,1.22) -1.48
4 0.93(0.79,1.11) 0.9(0.73,1.11) 0.91(0.74,1.12) -0.38
5 1.05(0.85,1.3) 1(0.78,1.28) 0.99(0.77,1.27) 1.34
6 0.83(0.67,1.02) 0.94(0.74,1.2) 0.95(0.75,1.2) -0.08
7 1.02(0.8,1.3) 0.98(0.75,1.28) 0.98(0.75,1.28) 0.12
8 1.02(0.82,1.27) 0.91(0.71,1.17) 0.91(0.71,1.17) -0.39
9 1.08(0.88,1.32) 1(0.79,1.28) 1(0.78,1.27) 0.71
10 1(0.82,1.22) 1(0.79,1.27) 1(0.79,1.27) -0.66
11 0.62(0.41,0.94) 0.87(0.56,1.36) 0.89(0.57,1.39) -1.58
12 1.43(1.12,1.84) 1.01(0.76,1.32) 1(0.76,1.31) 1.54
13 0.94(0.79,1.12) 0.95(0.77,1.17) 0.96(0.77,1.18) -0.62
14 0.77(0.64,0.92) 0.92(0.74,1.13) 0.93(0.75,1.14) -0.66
15 0.79(0.57,1.11) 0.88(0.61,1.27) 0.91(0.63,1.3) -1.53
16 1.04(0.81,1.34) 0.95(0.72,1.26) 0.96(0.72,1.27) -0.35
17 0.88(0.7,1.11) 0.9(0.69,1.17) 0.91(0.7,1.18) -0.73
18 0.92(0.79,1.07) 0.93(0.76,1.13) 0.94(0.77,1.14) 0.41
19 0.88(0.68,1.13) 0.99(0.75,1.31) 0.99(0.75,1.31) -0.65
20 0.74(0.57,0.97) 0.9(0.67,1.21) 0.91(0.68,1.22) -0.49
21 0.85(0.7,1.04) 0.93(0.73,1.17) 0.93(0.73,1.16) 0.29
22 1.12(0.91,1.38) 1.01(0.79,1.28) 1(0.79,1.26) 1.96
23 1.03(0.87,1.22) 0.97(0.79,1.2) 0.97(0.79,1.2) 0
24 0.95(0.82,1.11) 1.02(0.84,1.23) 1.01(0.83,1.22) 0.43
25 0.97(0.85,1.12) 0.9(0.76,1.08) 0.91(0.76,1.08) -1.63
26 1.08(0.94,1.25) 0.98(0.82,1.16) 0.97(0.82,1.16) 0.69
27 0.94(0.73,1.21) 0.88(0.66,1.18) 0.9(0.68,1.2) -0.88
28 0.93(0.75,1.15) 1(0.78,1.28) 1(0.78,1.27) 0.49
29 1.06(0.84,1.35) 0.96(0.73,1.25) 0.96(0.73,1.25) 0.16
30 0.55(0.29,1.04) 0.89(0.46,1.7) 0.93(0.49,1.78) -4.4
31 1(0.82,1.22) 0.85(0.66,1.08) 0.87(0.68,1.1) -0.36
32 0.88(0.77,1) 0.96(0.81,1.13) 0.96(0.81,1.13) 0.86
33 0.82(0.71,0.94) 0.94(0.79,1.11) 0.94(0.79,1.12) -0.37
Average (range) % reduction -0.21 (-4.40, 1.96)
Table C.4: Predictions of the treatment effect on OS obtained from the bivariate model (with PFS as surrogate endpoint) and the trivariate
model (with TR and PFS as two surrogate endpoints modelled jointly) presented alongside of the observed estimates for the base case
scenario (33 studies); % red refers to the percentage reduction in the width of the predicted interval when comparing the predicted effects
obtained from the trivariate model with the effects predicted using the bivariate model. The study index corresponds to the number in the
reference list for the base case scenario included in the supplementary materials.
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Subclass Study index* Observed OS bivariate trivariate structured %red
Systemic chemotherapy 1 0.99(0.88,1.12) 0.99(0.84,1.17) 0.99(0.84,1.16) 4.16
2 1.01(0.74,1.38) 1(0.71,1.39) 0.99(0.71,1.37) 1.85
4 0.93(0.79,1.11) 0.92(0.73,1.14) 0.93(0.74,1.15) 1.48
7 1.02(0.8,1.3) 0.98(0.75,1.27) 0.98(0.76,1.27) 1.01
8 1.02(0.82,1.27) 0.92(0.71,1.18) 0.92(0.71,1.18) -0.13
9 1.08(0.88,1.32) 1(0.78,1.26) 0.99(0.78,1.24) 3.22
10 1(0.82,1.22) 1(0.79,1.26) 1(0.79,1.25) 0.83
17 0.88(0.7,1.11) 0.93(0.71,1.21) 0.93(0.72,1.21) 1.7
18 0.92(0.79,1.07) 0.95(0.78,1.15) 0.95(0.78,1.15) 1.07
19 0.88(0.68,1.13) 0.99(0.75,1.3) 0.99(0.76,1.3) 0.39
20 0.74(0.57,0.97) 0.94(0.69,1.26) 0.94(0.7,1.26) 1.08
22 1.12(0.91,1.38) 0.99(0.79,1.25) 0.99(0.78,1.24) 3.14
23 1.03(0.87,1.22) 0.97(0.79,1.19) 0.97(0.79,1.19) 1.79
28 0.93(0.75,1.15) 1(0.78,1.27) 0.99(0.78,1.26) 2.42
30 0.55(0.29,1.04) 0.92(0.48,1.76) 0.96(0.5,1.82) -2.92
Average % reduction (range) 1.41 (-2.92,4.16)
Anti-EGFR 3 0.91(0.68,1.21) 0.88(0.59,1.28) 0.89(0.59,1.31) -4.82
6 0.83(0.67,1.02) 0.94(0.67,1.28) 0.95(0.67,1.32) -6.72
14 0.77(0.64,0.92) 0.92(0.7,1.2) 0.93(0.7,1.22) -6.72
21 0.85(0.7,1.04) 0.92(0.67,1.25) 0.92(0.65,1.28) -6.81
25 0.97(0.85,1.12) 0.89(0.68,1.15) 0.89(0.66,1.18) -10.33
29 1.06(0.84,1.35) 0.92(0.65,1.27) 0.93(0.64,1.32) -9.54
31 1(0.82,1.22) 0.85(0.62,1.15) 0.85(0.62,1.16) -0.77
32 0.88(0.77,1) 0.95(0.7,1.27) 0.96(0.69,1.32) -9.58
Average % reduction (range) -6.91 (-9.58,-0.77)
Antiangiogenic 5 1.05(0.85,1.3) 1.07(0.71,1.58) 1.07(0.71,1.56) 3.3
11 0.62(0.41,0.94) 0.83(0.47,1.43) 0.84(0.48,1.44) -0.07
12 1.43(1.12,1.84) 1.04(0.72,1.47) 1.03(0.72,1.44) 4.55
13 0.94(0.79,1.12) 0.97(0.66,1.38) 0.97(0.67,1.37) 3.34
15 0.79(0.57,1.11) 0.82(0.49,1.35) 0.84(0.5,1.36) -0.38
24 0.95(0.82,1.11) 1.11(0.78,1.55) 1.11(0.78,1.53) 2.46
26 1.08(0.94,1.25) 1.02(0.71,1.41) 1.01(0.72,1.39) 4.4
27 0.94(0.73,1.21) 0.81(0.53,1.23) 0.83(0.54,1.23) 1.67
33 0.82(0.71,0.94) 0.96(0.7,1.29) 0.96(0.7,1.29) 1.91
Average % reduction (range) 2.35 (-0.07,4.4)
Table C.5: Predicted treatment effects on OS obtained in the cross validation procedure in subgroup analyses (class of therapy) from the bivariate
model (with PFS as surrogate endpoint) and the trivariate model (with TR and PFS as two surrogate endpoints modelled jointly) presented
alongside of the observed estimates for the base case scenario (33 studies); % red refers to the percentage reduction in the width of the predicted
interval corresponding to the prediction from the trivariate model compared to the bivariate model. The study index corresponds to the number
in the reference list for the base case scenario included in the supplementary materials.
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Response OS Response PFS Response PFS PFS OS PFS OS
2D 2D 3D 2D 3D
All treatments
intercept -0.01(-0.05,0.04) -0.05(-0.14,0.03) -0.04(-0.12,0.03) 0(-0.05,0.05) 0.01(-0.03,0.05)
slope -0.09(-0.17,-0.02) -0.33(-0.46,-0.19) -0.33(-0.46,-0.21) 0.23(0.04,0.43) 0.27(0.1,0.44)
variance 0(0,0.01) 0.03(0.01,0.05) 0.02(0.01,0.04) 0(0,0.01) 0(0,0.01)
R2adjusted 0.39(0.02,0.85) 0.57(0.24,0.83) 0.59(0.28,0.83) 0.57(0.06,0.96) 0.57(0.13,0.94)
Systemic chemotherapy
intercept -0.01(-0.06,0.04) -0.06(-0.17,0.03) -0.04(-0.14,0.04) -0.02(-0.08,0.04) 0(-0.05,0.05)
slope -0.08(-0.17,-0.01) -0.25(-0.41,-0.08) -0.29(-0.43,-0.13) 0.17(0.01,0.45) 0.27(0.05,0.5)
variance 0(0,0.01) 0.02(0,0.07) 0.02(0,0.05) 0(0,0.01) 0(0,0.01)
R2adjusted 0.5(0.01,0.97) 0.54(0.06,0.94) 0.62(0.16,0.96) 0.53(0.01,0.98) 0.61(0.04,0.98)
Anti-EGFR therapies
intercept -0.05(-0.14,0.07) -0.21(-0.37,0.01) -0.15(-0.33,0.07) -0.04(-0.15,0.19) -0.02(-0.12,0.18)
slope -0.04(-0.17,0) -0.14(-0.36,-0.01) -0.18(-0.41,-0.02) 0.16(0,0.74) 0.17(0,0.74)
variance 0.01(0,0.04) 0.02(0,0.08) 0.02(0,0.1) 0.01(0,0.05) 0.01(0,0.04)
R2adjusted 0.21(0,0.83) 0.45(0,0.96) 0.49(0.01,0.96) 0.23(0,0.86) 0.21(0,0.84)
Anti-angiogenic agents
intercept 0.09(-0.07,0.33) 0.07(-0.14,0.29) 0.07(-0.13,0.29) 0.04(-0.06,0.14) 0.06(-0.04,0.17)
slope -0.47(-1.24,-0.03) -0.94(-1.82,-0.32) -0.9(-1.86,-0.24) 0.37(0.05,0.75) 0.41(0.04,0.85)
variance 0.04(0,0.16) 0.04(0,0.14) 0.03(0,0.12) 0.01(0,0.04) 0.01(0,0.06)
R2adjusted 0.43(0,0.94) 0.72(0.11,0.99) 0.64(0.06,0.98) 0.58(0.03,0.97) 0.54(0.02,0.96)
Table D.6: Surrogacy criteria: posterior means, between study variances and associated 95% Credible Intervals obtained from the bivariate
and structured trivariate models, applied to data where at least two outcomes are reported for each trial (51 trials); surrogate outcomes
TR: Treatment response rate, PFS: Progression free survival and final outcome OS: Overall survival
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Response OS Response OS PFS OS
2D 2D 2D 3D
All treatments
mean(OR(TR)) 1.48(1.2,1.81) 1.41(1.18,1.68) 1.42(1.21,1.67)
mean(HR(PFS)) 0.84(0.77,0.91) 0.83(0.76,0.9) 0.85(0.79,0.92)
mean(HR(OS)) 0.96(0.92,1) 0.95(0.91,1) 0.97(0.93,1)
τ2TR 0.32(0.18,0.56) 0.3(0.17,0.49) 0.27(0.16,0.44)
τ2PFS 0.06(0.03,0.11) 0.06(0.03,0.1) 0.05(0.03,0.09)
τ2OS 0.01(0,0.02) 0.01(0,0.02) 0.01(0,0.02)
Systemic chemotherapy
mean(OR(TR)) 1.3(0.92,1.79) 1.29(0.97,1.68) 1.3(1.01,1.65)
mean(HR(PFS)) 0.88(0.78,1) 0.89(0.77,1.02) 0.89(0.8,0.99)
mean(HR(OS)) 0.97(0.92,1.03) 0.96(0.9,1.02) 0.97(0.91,1.02)
τ2TR 0.43(0.18,0.95) 0.39(0.19,0.76) 0.34(0.17,0.64)
τ2PFS 0.05(0.02,0.12) 0.06(0.02,0.14) 0.05(0.02,0.1)
τ2OS 0.01(0,0.02) 0(0,0.02) 0.01(0,0.02)
Anti-EGFR therapies
mean(OR(TR)) 2.66(1.36,5.12) 2.13(1.23,3.65) 2.13(1.2,3.67)
mean(HR(PFS)) 0.72(0.62,0.83) 0.73(0.61,0.88) 0.76(0.65,0.9)
mean(HR(OS)) 0.93(0.85,1.01) 0.91(0.83,1.02) 0.93(0.86,1.03)
τ2TR 0.73(0.12,2.94) 0.62(0.13,2.19) 0.71(0.14,2.37)
τ2PFS 0.03(0,0.13) 0.06(0.01,0.22) 0.05(0.01,0.17)
τ2OS 0.01(0,0.04) 0.01(0,0.08) 0.01(0,0.05)
Anti-angiogenic agents
mean(OR(TR)) 1.31(1,1.75) 1.29(0.98,1.73) 1.28(1.04,1.61)
mean(HR(PFS)) 0.86(0.65,1.1) 0.83(0.67,1.01) 0.88(0.72,1.05)
mean(HR(OS)) 1(0.83,1.21) 0.97(0.85,1.08) 1.01(0.89,1.15)
τ2TR 0.15(0.02,0.5) 0.15(0.02,0.49) 0.1(0.01,0.29)
τ2PFS 0.16(0.04,0.45) 0.11(0.03,0.3) 0.1(0.03,0.26)
τ2OS 0.07(0,0.26) 0.03(0,0.1) 0.04(0,0.12)
Table D.7: Posterior means and between study variances and associated 95% Credible Intervals obtained from the bivariate and
structured trivariate models for each subclass therapy, using data where at least two outcomes are reported for each trial (51
trials); surrogate outcomes TR: Treatment response rate, PFS: Progression free survival and final outcome OS: Overall survival
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Appendix D.2. Set of 7 trials not allowing for crossover
2D TR PFS 2D TR OS 2D PFS OS 3D
mean(OR(TR)) 1.32(0.8,2.02) 1.32(0.76,2.08) 1.33(0.81,2.03)
mean(HR(PFS)) 0.88(0.73,1.06) 0.88(0.72,1.07) 0.88(0.73,1.05)
mean(HR(OS)) 0.94(0.83,1.06) 0.94(0.83,1.06) 0.93(0.83,1.06)
τ2TR 0.34(0.06,1.26) 0.41(0.07,1.58) 0.33(0.06,1.23)
τ2PFS 0.05(0.01,0.21) 0.05(0.01,0.2)
τ2OS 0.01(0,0.07) 0.01(0,0.06)
Table D.8: Mean effects and heterogeneity parameters obtained from the bivariate models and structured trivariate model applied to the
trials that did not crossover therapy (7 studies complete data)
Study index* Observed OS bivariate trivariate structured %red
2 1.01(0.74,1.38) 1(0.66,1.49) 0.99(0.65,1.46) 3.24
4 0.93(0.79,1.11) 0.84(0.59,1.16) 0.83(0.59,1.16) -0.31
5 1.05(0.85,1.3) 0.99(0.69,1.38) 0.97(0.69,1.35) 5.51
6 0.83(0.67,1.02) 0.94(0.68,1.28) 0.94(0.69,1.27) 1.77
7 1.02(0.8,1.3) 0.97(0.68,1.35) 0.97(0.68,1.36) -1.75
16 1.04(0.81,1.34) 0.93(0.66,1.3) 0.93(0.66,1.29) 1.63
33 0.82(0.71,0.94) 0.94(0.72,1.22) 0.94(0.73,1.2) 6.19
Average % reduction (range) 2.33(-1.74,6.19)
Table D.9: Predictions of the treatment effect on OS obtained from the bivariate model (with PFS as surrogate endpoint) and the trivariate
model (with TR and PFS as two surrogate endpoints modelled jointly) presented alongside of the observed estimates for 7 studies with no
cross over; % red refers to the percentage reduction in the width of the predicted interval when comparing the predicted effects obtained
from the trivariate model with the effects predicted using the bivariate model. The study index corresponds to the number in the reference
list for the base case scenario included in the supplementary materials.
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Appendix D.3. Set of 32 studies, sensitivity analysis results where outlier 1 study was removed (index 93)
Response OS Response PFS Response PFS PFS OS PFS OS
2D 2D 3D 2D 3D
All treatments
intercept -0.03(-0.08,0.02) -0.05(-0.14,0.03) -0.05(-0.14,0.02) -0.01(-0.06,0.04) -0.01(-0.06,0.03)
slope -0.06(-0.13,0) -0.32(-0.45,-0.19) -0.31(-0.43,-0.18) 0.28(0.08,0.48) 0.26(0.06,0.46)
variance 0(0,0.01) 0.02(0.01,0.05) 0.02(0.01,0.04) 0(0,0.01) 0(0,0.01)
R2adjusted 0.36(0,0.92) 0.6(0.24,0.86) 0.61(0.26,0.88) 0.68(0.15,0.98) 0.63(0.1,0.98)
Systemic chemotherapy
intercept -0.02(-0.08,0.04) -0.04(-0.16,0.06) -0.04(-0.14,0.05) -0.02(-0.08,0.04) -0.02(-0.08,0.04)
slope -0.03(-0.11,0) -0.26(-0.42,-0.08) -0.25(-0.4,-0.09) 0.17(0,0.45) 0.14(0,0.4)
variance 0(0,0.01) 0.02(0,0.08) 0.02(0,0.06) 0(0,0.01) 0(0,0.01)
R2adjusted 0.39(0,0.96) 0.58(0.07,0.96) 0.66(0.11,0.98) 0.52(0.01,0.98) 0.47(0,0.97)
Anti-EGFR therapies
intercept -0.08(-0.18,0.09) -0.21(-0.36,0.02) -0.19(-0.36,0.05) 0(-0.17,0.61) 0.03(-0.17,0.86)
slope -0.05(-0.21,0) -0.12(-0.37,0) -0.14(-0.4,-0.01) 0.38(0,2.3) 0.49(0,3.12)
variance 0.01(0,0.06) 0.02(0,0.08) 0.02(0,0.1) 0.01(0,0.05) 0.01(0,0.05)
R2adjusted 0.23(0,0.87) 0.39(0,0.94) 0.4(0,0.95) 0.28(0,0.9) 0.27(0,0.89)
Anti-angiogenic agents
intercept 0.04(-0.09,0.2) 0.03(-0.18,0.25) 0.03(-0.18,0.25) 0.02(-0.1,0.15) 0.02(-0.09,0.14)
slope -0.35(-0.89,-0.03) -0.87(-1.64,-0.3) -0.85(-1.64,-0.27) 0.38(0.05,0.79) 0.37(0.04,0.77)
variance 0.02(0,0.07) 0.04(0,0.15) 0.03(0,0.14) 0.02(0,0.06) 0.01(0,0.06)
R2adjusted 0.52(0.01,0.97) 0.74(0.13,0.99) 0.72(0.1,0.99) 0.59(0.03,0.97) 0.56(0.02,0.97)
Table D.10: Surrogacy criteri: posterior means, between study variances and associated 95% Credible Intervals obtained from the bivariate
and structured trivariate models, applied to data (33 trials), removing outlier trial indexed 93; surrogate outcomes TR: Treatment response
rate, PFS: Progression free survival and final outcome OS: Overall survival
Appendix D.4. Set of 33 studies, sensitivity analysis results where the prior for between-study correlation is set to
U(-1,1)
Appendix E. Results of alternative trivariate model parameterisations
A sensitivity analysis to the structure of the between-studies variance-covariance matrix, was carried out. In
the main analysis, the between-studies model (in the product normal formulation described by Eq. (2) of the main
manuscript), we assumed conditional independence between the true treatment effect on the first surrogate endpoint
(TR and the treatment effect on the final outcome (OS). In this sensitivity analysis, two alternative parameterisations
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Response OS Response PFS Response PFS PFS OS PFS OS
2D 2D 3D 2D 3D
All treatments
intercept -0.03(-0.08,0.02) -0.05(-0.14,0.03) -0.05(-0.13,0.02) -0.01(-0.06,0.03) -0.02(-0.07,0.03)
slope -0.04(-0.13,0.02) -0.32(-0.45,-0.2) -0.31(-0.43,-0.19) 0.22(0.02,0.41) 0.19(0,0.4)
variance 0(0,0.01) 0.02(0.01,0.05) 0.02(0.01,0.04) 0(0,0.01) 0(0,0.01)
R2adjusted 0.31(0,0.9) 0.61(0.27,0.87) 0.64(0.3,0.89) 0.58(0.05,0.97) 0.49(0.01,0.95)
Systemic chemotherapy
intercept -0.03(-0.09,0.03) -0.05(-0.16,0.05) -0.04(-0.14,0.05) -0.02(-0.08,0.04) -0.02(-0.08,0.04)
slope -0.02(-0.1,0.04) -0.26(-0.42,-0.07) -0.25(-0.4,-0.09) 0.14(-0.07,0.44) 0.1(-0.1,0.39)
variance 0(0,0.01) 0.03(0,0.08) 0.02(0,0.06) 0(0,0.01) 0(0,0.01)
R2adjusted 0.35(0,0.96) 0.58(0.05,0.96) 0.66(0.11,0.98) 0.49(0,0.98) 0.43(0,0.97)
Anti-EGFR therapies
intercept -0.13(-0.3,0.02) -0.23(-0.44,0) -0.21(-0.43,0.01) -0.15(-0.42,0.05) -0.17(-0.57,0.06)
slope 0.03(-0.1,0.2) -0.12(-0.35,0.08) -0.13(-0.35,0.07) -0.14(-0.91,0.38) -0.24(-1.41,0.41)
variance 0.01(0,0.04) 0.02(0,0.08) 0.02(0,0.09) 0.01(0,0.04) 0.01(0,0.04)
R2adjusted 0.32(0,0.95) 0.42(0,0.95) 0.47(0,0.97) 0.32(0,0.95) 0.35(0,0.96)
Anti-angiogenic agents
intercept 0.03(-0.11,0.2) 0.03(-0.2,0.25) 0.03(-0.19,0.25) 0.02(-0.1,0.14) 0.02(-0.1,0.14)
slope -0.33(-0.91,0.09) -0.86(-1.63,-0.25) -0.85(-1.65,-0.24) 0.37(-0.01,0.79) 0.35(-0.03,0.78)
variance 0.02(0,0.07) 0.04(0,0.16) 0.03(0,0.14) 0.02(0,0.06) 0.01(0,0.06)
R2adjusted 0.5(0,0.97) 0.73(0.09,0.99) 0.72(0.09,0.99) 0.58(0.01,0.97) 0.54(0.01,0.96)
Table D.11: Surrogacy criteria: posterior means, between study variances and associated 95% Credible Intervals obtained from the bivariate
and structured trivariate models, applied to data where all three outcomes are reported for each trial (33 trial)-Prior for between-studies
correlation: U(-1,1); surrogate outcomes TR: Treatment response rate, PFS: Progression free survival and final outcome OS: Overall
survival
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were used. In the first one (denoted in Table 10 as 3D structured **) we assumed conditional independence of the
true treatment effect on the surrogate endpoints (TR and PFS) whilst the treatment effect on the final outcome was
conditional on both treatment effects on the two surrogate endpoints. The second model in sensitivity analysis assumed
fully unstructured between-studies variance-covariance matrix, hence the true treatment effects on all three outcomes
being correlated.
PFS OS PFS OS PFS OS PFS OS
2D 3D structured∗ 3D structured∗∗ 3D unstructured
intercept -0.02(-0.06,0.03) -0.02(-0.06,0.03) -0.02(-0.06,0.03) -0.06(-0.14,0.01)
slope 0.22(0.03,0.41) 0.19(0.02,0.4) 0.13(0.01,0.33) 0.29(-0.01,0.73)
variance 0(0,0.01) 0(0,0.01) 0(0,0.01) 0(0,0.01)
R2adjusted 0.58(0.06,0.97) 0.5(0.02,0.95) 0.35(0,0.87) 0.37(0.04,0.89)
DIC -116.92(-136.5,-95.37) -117.61(-144.9,-87.1) -119.96(-146.6,-91.58) -120.77(-148,90.75)
Table E.12: Surrogacy criteria obtained from the bivariate, structured trivariate model∗ as described in the manuscript (assuming con-
ditional independence between true effects on Response and on OS), the new structured model ∗∗ (assuming conditional independence
between true effects on Response and on PFS) and the unstructured model (no structure between the true effects on surrogate endpoints)
applied to the complete dataset (33 studies)
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